EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.103073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Liping Chu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China; Gene Editing Center, School of Life Science and T…. Hauptthemen laut MEDLINE: Gain of Function Mutation, Lymphoma, B-Cell, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, ShanghaiTech University.
Abstract (Originalsprache)
Polycomb repressive complex 2 (PRC2) suppresses gene transcription by methylating lysine 27 of histone H3 (H3K27) and plays critical roles in embryonic development. Among the core PRC2 subunits, EZH2 is the catalytic subunit and EED allosterically activates EZH2 upon binding trimethylated H3K27 (H3K27me3). Activating mutations on Y641, A677, and A687 within the enzymatic SET (Su(Var)3 to 9, Enhancer-of-zeste, and Trithorax) domain of EZH2 have been associated with enhanced H3K27me3 and tumorigenicity of many cancers including B-cell lymphoma and melanoma. To tackle the critical residues outside the EZH2 SET domain, we examined EZH2 mutations in lymphoma from cancer genome databases and identified a novel gain-of-function mutation W113C, which increases H3K27me3 in vitro and in vivo and promotes CDKN2A silencing to a similar level as EZH2 Y641F. Different from other gain-of-function mutations, this mutation is located in the SET-activation loop at the EZH2 N terminus, which stabilizes the SET domain and facilitates substrate binding. This may explain how the W113C mutation increases PRC2 activity. Tazemetostat is a Food and Drug Administration-approved EZH2-binding inhibitor for follicular lymphoma treatment. Intriguingly, the W113C mutation leads to tazemetostat resistance in both H3K27 methylation and tumor proliferation. Another class of allosteric PRC2 inhibitor binding EED overcomes the resistance, effectively decreases H3K27me3, and blocks tumor proliferation in cells expressing EZH2 W113C. As this mutation is originally identified from lymphoma samples, our results demonstrated its activating characteristic and the deleterious consequence, provide insights on PRC2 regulation, and support the continued exploration of treatment optimization for lymphoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China; Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
- Jing Medicine, Shanghai, China.
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China. Electronic address: blsong@whu.edu.cn.
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China. Electronic address: qiwei@shanghaitech.edu.cn.
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- ShanghaiTech University
Zitieren
APA
Chu, L., Tan, D., Zhu, M., Qu, Y., Ma, X., Song, B. L., & Qi, W. (2023). EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.103073
Vancouver
Chu L, Tan D, Zhu M, Qu Y, Ma X, Song BL, et al. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.103073
BibTeX
@article{Chu2023,
author = {Chu, Liping and Tan, Dongxia and Zhu, Meimei and Qu, Yuxiu and Ma, Xin and Song, Bao-Liang and Qi, Wei},
title = {EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.103073}
}
EUVIMED